Study guide
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment
Key Takeaways Explain This Topic AI
A major depressive episode (DSM-5) requires at least 5 of 9 symptoms for at least 2 weeks, including depressed mood or anhedonia; somatic features include early morning waking, diurnal mood variation, weight loss and psychomotor change.
NICE NG222 divides depression into less severe (PHQ-9 below 16), treated first with options such as guided self-help or group CBT, and more severe (16 or more), where combined individual CBT and an antidepressant is the first option; sertraline is preferred after MI.
SSRIs take 2–4 weeks to work and can transiently increase agitation and suicidal thoughts; review within 1 week if aged 18–25 or at increased suicide risk (otherwise within 2 weeks) and continue for at least 6 months after remission.
Acute mania requires immediate cessation of antidepressants and initiation of an oral atypical antipsychotic or valproate; lithium is the gold-standard maintenance agent reducing suicide risk (target 0.6–0.8 mmol/L).
NICE NG225 (2022) advises against risk scales or low/medium/high risk stratification to predict suicide; instead complete a psychosocial assessment and safety plan, with previous self-harm the strongest predictor, escalating to CRHTT or admission according to needs.
Last updated: October 2026
Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment
Mood disorders represent common presentations across acute hospital medicine and primary care. Differentiating unipolar depression from bipolar spectrum illness, managing antidepressant pharmacology safely, monitoring narrow-therapeutic-index mood stabilisers, and conducting robust suicide risk stratification are core competencies in clinical practice.
Major Depressive Disorder (MDD): Diagnostic Criteria & Stratification
Under DSM-5 , a major depressive episode needs at least 5 of 9 symptoms for at least 2 weeks , including depressed mood or anhedonia , causing clinically significant distress or impairment. ICD-11 uses a similar threshold (at least 5 symptoms, including at least one affective symptom). The older ICD-10 framing, still common in UK teaching, requires at least 2 of 3 "core" symptoms (low mood, anhedonia, fatigue) plus additional symptoms.
Core & Somatic Features
Core Symptoms:
Depressed mood: Pervasive low mood for most of the day, nearly every day.
Anhedonia: Markedly diminished interest or pleasure in all or most activities.
Fatigue / Anergia: Decreased energy (a core symptom in ICD-10; one of the nine DSM-5 symptoms).
Biological & Cognitive Symptoms (Somatic Features):
Sleep disruption: Classically early morning awakening (EMA) , waking ≥2 hours before habitual wake time; initial or middle insomnia (or hypersomnia) may also occur.
Diurnal mood variation: Mood characteristically worst in the morning, improving slightly as the day progresses.
Weight and appetite changes: Significant anorexia and weight loss (>5% in a month), or increased appetite.
Psychomotor changes: Retardation (slowed speech, delayed responses) or agitation (pacing, hand-wringing).
Cognitive symptoms: Feelings of worthlessness, excessive inappropriate guilt, impaired concentration, and recurrent thoughts of death or suicide.
Severity Stratification & Scoring
The Patient Health Questionnaire-9 (PHQ-9) scores 0–27 (5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe). NICE NG222 (2022) simplifies treatment choice into two groups:
Less severe depression: PHQ-9 below 16 (covers what was previously called subthreshold and mild depression).
More severe depression: PHQ-9 16 or more (previously moderate and severe depression). Severe depression may have psychotic features (mood-congruent delusions of poverty, guilt or nihilism, including Cotard's syndrome), which need urgent specialist referral.
NICE NG222 Management Framework
Assessment: Exclude organic causes (hypothyroidism, B12 deficiency, Cushing's syndrome, hypercalcaemia, drugs such as corticosteroids), assess suicide risk, and agree a shared treatment decision. Encourage sleep hygiene, physical activity and alcohol reduction.
Less severe depression: Offer a menu of options in order of cost-effectiveness: guided self-help , group cognitive behavioural therapy (CBT) or group behavioural activation, individual CBT or behavioural activation, group exercise, group mindfulness or meditation, interpersonal psychotherapy (IPT), SSRIs , counselling, and short-term psychodynamic psychotherapy. Do not routinely offer antidepressants first-line for less severe depression unless that is the person's preference.
More severe depression: Options start with a combination of individual CBT and an antidepressant , then individual CBT, individual behavioural activation, an antidepressant alone (SSRI, SNRI or other), IPT, and others, chosen with the person.
Chronic, relapsing or treatment-resistant depression, or psychotic features: consider combined treatment, specialist mental health referral and, for severe or life-threatening depression, electroconvulsive therapy (ECT).
Antidepressant Pharmacotherapy: Classes & Comparison
Antidepressant Class Common Examples Mechanism of Action Clinical Indications & First-Line Roles Notable Adverse Effects & Prescribing Caveats
SSRIs Sertraline , Citalopram , Fluoxetine , Paroxetine Selective serotonin reuptake inhibition (blocks SERT) First-line for moderate-to-severe depression. Sertraline is safest post-myocardial infarction / unstable coronary disease. Fluoxetine is preferred in children and adolescents. GI upset, sexual dysfunction, hyponatraemia (SIADH in elderly), increased gastrointestinal bleeding. Citalopram causes dose-dependent QT prolongation (maximum 20 mg in elderly or hepatic impairment).
SNRIs Venlafaxine , Duloxetine Serotonin and noradrenaline reuptake inhibition Second-line for severe refractory depression; Duloxetine is effective for diabetic neuropathic pain. Dose-dependent hypertension (monitor BP, especially at venlafaxine >150 mg/day); severe discontinuation syndrome upon sudden cessation.
NaSSA Mirtazapine Central presynaptic alpha-2 adrenoceptor antagonist; blocks 5-HT2 and 5-HT3 Severe depression with prominent insomnia and anorexia; minimal sexual dysfunction. Marked sedation (via H1 blockade, paradoxically stronger at lower 15 mg dose) and weight gain ; minimal sexual side effects.
TCAs Amitriptyline , Lofepramine , Clomipramine Non-selective 5-HT & NA reuptake inhibition; anticholinergic & alpha-1 blockade Third-line refractory depression, neuropathic pain, migraine prophylaxis; Clomipramine in severe OCD. Anticholinergic toxidrome (dry mouth, urinary retention, blurred vision, constipation), postural hypotension. Highly fatal in overdose due to myocardial sodium channel blockade causing QRS widening and ventricular arrhythmias. Lofepramine has lowest cardiotoxicity.
MAOIs Phenelzine , Tranylcypromine, Moclobemide Inhibition of monoamine oxidase enzymes Refractory or atypical depression under specialist psychiatric supervision. Risk of fatal hypertensive crisis ("cheese reaction") with dietary tyramine (mature cheeses, yeast extracts, red wine); requires strict 2-week washout before switching agents (5 weeks after fluoxetine).
- SSRI Prescribing Rules, Discontinuation & Serotonin Syndrome
- Prescribing & Review Guidelines
Delayed Onset: SSRIs require 2 to 4 weeks for therapeutic effect. Counsel patients that physical activation often precedes mood elevation, transiently increasing anxiety, agitation, and suicidal thoughts.
Review Frequency (NICE NG222): Review within 1 week of starting an antidepressant for people aged 18 to 25 or at increased risk of suicide; otherwise usually within 2 weeks , then regularly (for example every 2–4 weeks in the first 3 months).
Treatment Duration: Continue therapy at full therapeutic dose for at least 6 months after full remission of a first episode to prevent relapse (≥2 years if recurrent depression).
Discontinuation Syndrome
Abrupt cessation (especially short half-life drugs like paroxetine and venlafaxine ) causes the FINISH syndrome:
F lu-like symptoms, I nsomnia, N ausea, I mbalance (dizziness/vertigo), S ensory disturbances ( electric shock sensations / "brain zaps" ), and H yperarousal (anxiety/agitation). Taper gradually over at least 4 weeks. Fluoxetine carries the lowest risk due to its long-acting metabolite norfluoxetine (half-life 7–14 days).
Serotonin Syndrome
Caused by excessive 5-HT receptor stimulation, typically when combining serotonergic agents (SSRI + MAOI, tramadol, St John's Wort, linezolid, triptans).
Hunter Criteria Triad:
Neuromuscular excitation: Spontaneous clonus, inducible clonus, ocular clonus , hyperreflexia, and tremor.
Autonomic instability: Hyperthermia (>38°C), profuse diaphoresis, tachycardia, labile BP, and diarrhoea.
Altered mental status: Agitation, restlessness, delirium.
Management: Stop all serotonergic agents immediately; supportive IV fluids (0.9% normal saline); IV benzodiazepines for agitation; cyproheptadine (5-HT2A antagonist) for moderate-to-severe cases; ICU admission and paralysis if temperature >41°C.
Bipolar Affective Disorder: Subtypes & Management
Bipolar I Disorder: At least one episode of mania . Manic episodes involve elevated/irritable mood and increased energy lasting ≥7 days (or requiring hospitalisation), with grandiosity, decreased need for sleep, pressured speech, flight of ideas, distractibility, and reckless spending/disinhibition. Often features psychotic symptoms.
Bipolar II Disorder: At least one episode of hypomania (lasting ≥4 days , without severe functional impairment, hospitalisation, or psychotic symptoms) alternating with major depressive episodes.
Acute Mania Management
Stop Antidepressants: Discontinue all antidepressants immediately to avoid fueling manic excitation.
First-Line Pharmacotherapy: Initiate an oral atypical antipsychotic ( olanzapine , risperidone , quetiapine ) or haloperidol .
Alternative / Mood Stabiliser: Oral semi-sodium valproate or lithium.
Caution
Valproate Absolute Teratogenicity Warning: Sodium valproate is strictly contraindicated in females of childbearing potential unless enrolled in the mandatory Pregnancy Prevention Programme. It carries a 10% risk of major congenital malformations (neural tube defects, facial clefts) and a 30–40% risk of neurodevelopmental disorders.
Lithium Carbonate: Monitoring Protocol & Toxicity Management
Lithium is the gold-standard maintenance mood stabiliser, uniquely proven to reduce completed suicide rates.
Therapeutic Window & Routine Monitoring
Therapeutic Levels: Maintenance target 0.6 to 0.8 mmol/L (0.8 to 1.0 mmol/L in acute mania or frequent relapses).
Timing: Draw blood samples precisely 12 hours post-dose (trough level).
Frequency (NICE CG185): Measure 1 week after starting and after each dose change, then weekly until stable; then every 3 months for the first year , and every 6 months after that (every 3 months for higher-risk groups such as older people, those on interacting drugs, or with impaired renal or thyroid function).
Organ Surveillance: Check renal function ( eGFR/creatinine ), thyroid function ( TSH ) and calcium every 6 months , plus weight or BMI. Long-term risks include nephrogenic diabetes insipidus (polyuria/polydipsia), hypothyroidism, hyperparathyroidism, and first-trimester teratogenicity ( Ebstein's anomaly ).
Lithium Toxicity Precipitants & Management
Precipitated by dehydration, sodium depletion, and drugs reducing renal clearance: thiazide diuretics (highest risk), NSAIDs , and ACE inhibitors / ARBs .
Toxicity Features:
Mild-to-Moderate (1.5–2.0 mmol/L): Coarse tremor , ataxia, dysarthria, nausea, vomiting, diarrhoea.
Severe (>2.0 mmol/L): Hyperreflexia, seizures, arrhythmias, acute renal failure, coma.
Management: Stop lithium; aggressive IV rehydration with 0.9% normal saline (promotes lithium excretion); discuss extracorporeal treatment (haemodialysis) with TOXBASE or the National Poisons Information Service; the EXTRIP workgroup recommends it if lithium is above 4.0 mmol/L with impaired kidney function , or with decreased consciousness, seizures or life-threatening dysrhythmias whatever the level.
Suicide & Self-Harm Risk Assessment
NICE NG225 (Self-harm, 2022) changed UK practice: do not use risk assessment tools or scales, or global stratification into low, medium or high risk , to predict future suicide or repeat self-harm, or to decide who receives treatment or is discharged. Instead, carry out a psychosocial assessment of needs and risks and plan care around them:
Assessment Domains: Intent (desire to die versus self-harm), plan, lethality of method, access to means (medications, firearms, ligature points), preparations (suicide note, updating a will, sorting finances), previous self-harm or suicide attempts (the strongest single predictor of future suicide) , hopelessness, mental disorder, substance misuse, social circumstances and protective factors (children, family support, beliefs).
Safety Planning: Develop a written safety plan with the person (warning signs, coping strategies, people and places that help, crisis contacts such as NHS 111 option 2, Samaritans 116 123, the GP) and agree means restriction (for example limited quantities of medication).
Escalation According to Needs: Clinical judgement about current needs and safety, not a risk category, decides the setting: follow-up in primary care; urgent referral to the Crisis Resolution and Home Treatment Team (CRHTT) or liaison psychiatry; or admission. Admission is informal if the person has capacity and consents; detention under the Mental Health Act 1983 (Section 2, 3 or 4) may be needed if a person with a mental disorder refuses admission and is at serious risk.